Study Design
DesignRandomized, double-blind, active-controlled
Randomization1:1
BlindingDouble-blind
Enrollment743
Duration48 weeks
Treatment Arms
Bimekizumab 320mg 320mg SC q4w (Wk 0-16), then q4w or q8w n=373
Secukinumab 300mg 300mg SC weekly (Wk 0-4), then q4w n=370
[{"id":"pasi100-w16","name":"PASI 100 at Week 16","type":"PRIMARY","unit":"%","results":[{"value":61.7,"arm_id":"bimzelx-arm","p_value":0.001,"vs_placebo":"vs secukinumab"},{"value":48.9,"arm_id":"sec-arm"}],"timepoint":"Week 16","description":"Percentage of patients achieving complete skin clearance (100% improvement in PASI score) at 16 weeks."}]
KEY STUDY: Direct H2H proving IL-17A/F > IL-17A alone. PASI 100 gap WIDENED from 13 pts (Wk16) to 21 pts (Wk48). Crossover data (Wk48→96): Cosentyx patients who switched to Bimzelx improved from 52.8% to 76.6% PASI 100 — direct proof IL-17F was sustaining residual disease. Thrush trade-off real but manageable.